SparingVision, a French biotech company focused on gene therapy in ophthalmology, has raised 44.5 million euros in financing. The investors include Jeito Capital.
Source: Press Release
SparingVision nabs funding
SparingVision, a French biotech company focused on gene therapy in ophthalmology, has raised 44.5 million euros in financing.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: